<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00446693</url>
  </required_header>
  <id_info>
    <org_study_id>EFPS01</org_study_id>
    <nct_id>NCT00446693</nct_id>
  </id_info>
  <brief_title>Clinical Investigation to Evaluate Safety and Performance of the EndoFast Reliant™ System in Vaginal Wall Reinforcement</brief_title>
  <official_title>A Single Arm, Multi-center, Prospective Clinical Investigation to Evaluate Safety and Performance of the EndoFast Reliant™ System in Vaginal Wall Reinforcement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endogun Medical Systems Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endogun Medical Systems Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to clinically assess the safety and performance of the EndoFast&#xD;
      Reliant™ system as a less invasive treatment for Pelvic Organ Prolapse.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      Pelvic Organ Prolapse represents a significant problem worldwide and may have a significant&#xD;
      negative impact on a woman's quality of life. The uterus, rectum and the bladder are held in&#xD;
      their normal positions just above the inner end of the vagina by a &quot;hammock&quot; made up of&#xD;
      supportive muscles and ligaments. Wear and tear on these supportive structures in the pelvis&#xD;
      can allow the uterus, the bladder, the bowels, the vaginal vault or the rectum to sag through&#xD;
      the muscle and ligament layers. When this occurs, the rectum, uterus, bowels or bladder can&#xD;
      create a bulge into the vagina. In severe cases, it is possible for the sagging rectum,&#xD;
      uterus, bowels or bladder to work its way down far enough that the bulge can appear at the&#xD;
      vagina's opening or even protrude from the opening. Pelvic Organ Prolapse causes significant&#xD;
      discomfort to the patients being associated with urinary incontinence, voiding difficulty&#xD;
      culminating with urinary retention, constipation, pain during sexual intercourse, local&#xD;
      discomfort, etc.&#xD;
&#xD;
      Treatment Options When symptoms occur, many patients initially opt for conservative&#xD;
      treatment. Pelvic exercises and vaginal support are the current mainstays of non surgical&#xD;
      management. In addition, patients who are poor surgical candidates or are strongly&#xD;
      disinclined to surgery can be offered vaginal support (pessaries) for symptom relief. Topical&#xD;
      estrogen is an important adjunct in the conservative management of patients with Pelvic Organ&#xD;
      Prolapse. However, the primary management strategy for severe Pelvic Organ Prolapse is&#xD;
      surgical. The exact treatment choice will depend on the severity of the prolapse and whether&#xD;
      there are any related pelvic floor defects.&#xD;
&#xD;
      Endogun Medical Systems Ltd. has developed an innovative, minimally-invasive system for&#xD;
      repair of Pelvic Floor Prolapse. The EndoFast Reliant™ system is a new concept of reinforcing&#xD;
      the vaginal wall with a proprietary system comprised of a mesh and soft tissue fasteners in a&#xD;
      minimally-invasive way. The fasteners can be deployed easily and swiftly in narrow spaces&#xD;
      into soft tissue and can support substantially more weight than needed for Pelvic Organ&#xD;
      Prolapse repair. Following many pre-clinical tests, the EndoFast Reliant™ system is now&#xD;
      available for clinical evaluation.&#xD;
&#xD;
      The objective of this study is to evaluate the safety and performance of the EndoFast&#xD;
      Reliant™ system for treatment of Pelvic Organ Prolapse.&#xD;
&#xD;
      In particular:&#xD;
&#xD;
        -  The study's primary goal is to clinically assess the safety of the EndoFast Reliant™ as&#xD;
           a minimally-invasive procedure for vaginal wall reinforcement.&#xD;
&#xD;
        -  The study's secondary goal is to clinically evaluate the performance of the EndoFast&#xD;
           Reliant™ system as a minimally-invasive procedure for vaginal wall reinforcement by&#xD;
           evaluating the improvement in Pelvic Organ Prolapse using the POPQ grading system.&#xD;
&#xD;
      Study Procedures and Follow up:&#xD;
&#xD;
      Pre-treatment tests and inspection will be performed within 4 months prior to surgery.&#xD;
&#xD;
      Approximately two weeks, three months and six months after the surgery the patient will be&#xD;
      invited for physician examination and laboratory tests.&#xD;
&#xD;
      Additional Study Measures:&#xD;
&#xD;
      In addition to the endpoint parameters, the following study measures will be collected:&#xD;
&#xD;
        -  Symptoms relief and Quality of Life (QOL) considerations.&#xD;
&#xD;
        -  Sexual Function considerations, as documented using the Female Sexual Function (FSFI)&#xD;
           questionnaire;&#xD;
&#xD;
        -  Assessment of the physician's satisfaction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety is defined as paucity of major device-related complications.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Performance as defined by relative improvement in Pelvic Organ Prolapse staging (as reported post operatively versus preoperatively) using the POPQ grading system.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Pelvic Organ Prolapse</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of EndoFast Reliant System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EndoFast Reliant™ system for Pelvic Organ Prolapse repair</intervention_name>
    <description>The EndoFast Reliant™ system is a new concept of reinforcing the vaginal wall with proprietary mesh and soft-tissue Fasteners in a minimally-invasive procedure.</description>
    <arm_group_label>I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female aged between 40-80 years (inclusive) who is not pregnant or planning to have&#xD;
             further births.&#xD;
&#xD;
          -  Subject suffers from Pelvic Organ Prolapse confirmed by vaginal inspection.&#xD;
&#xD;
          -  Patient under reliable form of contraceptive measure or menopausal.&#xD;
&#xD;
          -  Subject able to comprehend procedure and has signed Informed Consent Form for&#xD;
             participation in this study.&#xD;
&#xD;
          -  Subject able to complete the applicable questionnaires.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Planned to undergo hysterectomy.&#xD;
&#xD;
          -  Uterine prolapse equal to or greater than 3rd degree.&#xD;
&#xD;
          -  Documented Stress Urinary Incontinence on physical examination with full bladder or&#xD;
             during complete urodynamic assessment with and without prolapse reduction.&#xD;
&#xD;
          -  Any chronic active and uncontrolled disease.&#xD;
&#xD;
          -  Vaginal bleeding disorders.&#xD;
&#xD;
          -  Needing emergency surgery.&#xD;
&#xD;
          -  Any acute disease.&#xD;
&#xD;
          -  Blood clotting disorders and/or anticoagulant treatment.&#xD;
&#xD;
          -  Known cognitive or psychiatric disorder.&#xD;
&#xD;
          -  High operative risk.&#xD;
&#xD;
          -  Any ongoing malignant disease.&#xD;
&#xD;
          -  Concurrent participation in any other clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Von Theobald, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professeur d'Université-Praticien Hospitalier, gynécologie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michel Cosson, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Jeanne de Flandre - CHRU Gynécologie obstétrique</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Genadi Bitman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Jeanne de Flandre - CHRU Gynécologie obstétrique</name>
      <address>
        <city>Lille</city>
        <zip>56037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <study_first_submitted>March 12, 2007</study_first_submitted>
  <study_first_submitted_qc>March 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2007</study_first_posted>
  <last_update_submitted>November 18, 2009</last_update_submitted>
  <last_update_submitted_qc>November 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Miron Livneh VP Clinical and Medical affairs</name_title>
    <organization>Endogun Medical Systems Ltd.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

